Navigation Links
Thyroid Hormone Could One Day Treat Osteoporosis
Date:3/10/2008

ings of the National Academy of Sciences.

There had been a fear that injections of TSH would release thyroid hormones, which could have unwanted effects. However, Zaidi and his colleagues found that this was not the case with the animals they studied.

Zaidi said TSH is already used in humans to treat thyroid disorders. "We might be able to use the same drug for different purposes, a much larger purpose than it has ever been employed for," he said.

Dr. Stephen Honig, director of the Osteoporosis Center at the Hospital for Joint Diseases in New York City, said the idea of treating the bone disease with TSH is intriguing. But, it's far from certain that the beneficial effects seen in rodents would apply to humans. And other problems related to the use of TSH would need to be solved, he said.

"This is a very interesting animal study that strongly suggests that thyroid stimulating hormone may have anti-reabsorption effects on bone," Honig said. However, he noted that TSH can cause hyperthyroidism -- an overactive thyroid gland -- that can unleash serious problems with the body's metabolism.

"One question for TSH will be how often will it induce hyperthyroidism and can dose adjustments minimize this without impacting its bone-strengthening effects," Honig said. "The [study] authors suggest that, so far, hyperthyroidism has not been a problem, at least in a group of postmenopausal women being treated with TSH for thyroid cancer."

More information

For more on osteoporosis, visit the U.S. National Library of Medicine.



SOURCES: Mone Zaidi, M.D., Ph.D., professor of medicine and physiology, and director, Mount Sinai Bone Program, Mount Sinai School of Medicine, New York City; Stephen Honig, M.D., director, Osteoporosis Center, Hospital for Joint Diseases, New York City; March
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?
2. Newly discovered role of thyroid hormone during pregnancy
3. Combination of Thyroid Medicines Not Necessary
4. Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl
5. Early detection critical in treating pediatric thyroid cancer
6. Thyroid treatment no quick fix for weight loss in children
7. Better detection accounts for increase in cases of thyroid cancer
8. Thyroid Test Wont Help Pregnant Mom, Baby
9. Fluoride Damages the Thyroid, Report Shows
10. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
11. Low levels of PYY hormone a very early indicator of type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Thyroid Hormone Could One Day Treat Osteoporosis
Thyroid Hormone Could One Day Treat Osteoporosis
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 2Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 3Health News:Blues CEO Encourages Graduates to Stay and Lead Michigan 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 3Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 4Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 2Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 3Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 4Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8